Antihypercholesterolemic and antioxidant efficacies of zerumbone on the formation, development, and establishment of atherosclerosis in cholesterol-fed rabbits

Drug Design, Development and Therapy

Volumn 9, Issue , 2015, Pages 4173-4208

  Hemn, Hassan Othman ^a,b   Noordin, Muhammad Mustapha ^a   Rahman, Heshu Sulaiman ^a,b   Hazilawati, Hamza ^a   Zuki, Abubakr ^a   Chartrand, Max Stanley ^c  

^a UNIVERSITY PUTRA MALAYSIA   (Malaysia)

^b UNIVERSITY OF SULAIMANI   (Iraq)

^c Behavioral Research   (United States)

Author keywords

Antihypercholesterolemic; Antioxidant; Atherosclerosis; Rabbit model; Zerumbone

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; CREATININE; ERYTHROCYTE SUPEROXIDE DISMUTASE; FREE RADICAL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; SIMVASTATIN; SUPEROXIDE DISMUTASE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UREA; ZERUMBONE; ANTIOXIDANT; CHOLESTEROL INTAKE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LIPID; SESQUITERPENE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERCHOLESTEROLEMIC ACTIVITY; ANTIOXIDANT ACTIVITY; AORTA ATHEROSCLEROSIS; ARTICLE; ATHEROSCLEROTIC PLAQUE; ATHEROSCLEROTIC PLAQUE SIZE; CARDIOVASCULAR PARAMETERS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG MEGADOSE; ENZYME ACTIVITY; HEART INFARCTION; HISTOPATHOLOGY; HYPERCHOLESTEROLEMIA; LIPID PEROXIDATION; LIPID STORAGE; LIVER DISEASE; LOW DRUG DOSE; MALE; MORPHOMETRICS; NEW ZEALAND WHITE (RABBIT); NONHUMAN; OXIDATIVE STRESS; PROPHYLAXIS; TRIACYLGLYCEROL BLOOD LEVEL; ULTRASTRUCTURE; ZINGIBER ZERUMBET; ANIMAL; AORTA; AORTIC DISEASES; ATHEROSCLEROSIS; BLOOD; CHOLESTEROL INTAKE; DIETARY SUPPLEMENT; DISEASE MODEL; DRUG EFFECTS; METABOLISM; PATHOLOGY; RABBIT; TIME FACTOR;

ANIMALS; ANTICHOLESTEREMIC AGENTS; ANTIOXIDANTS; AORTA; AORTIC DISEASES; ATHEROSCLEROSIS; BIOMARKERS; CHOLESTEROL, DIETARY; DIETARY SUPPLEMENTS; DISEASE MODELS, ANIMAL; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; MALE; MALONDIALDEHYDE; OXIDATIVE STRESS; PLAQUE, ATHEROSCLEROTIC; RABBITS; SESQUITERPENES; SIMVASTATIN; SUPEROXIDE DISMUTASE; TIME FACTORS;

EID: 84939794028     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S76225     Document Type: Article

References (71)

1. Steinberg D. Atherogenesis in perspective: hypercholesterolemia and inflammation as partners in crime. Nat Med. 2002;8:1211–1217.
2. Holvoet P, Mertens A, Verhamme P, et al. Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arterioscler Thromb Vasc Biol. 2001;21:844–848.
3. Meisinger C, Baumert J, Khuseyinova N, Loewel H, Koenig W. Plasma oxidized low-density lipoprotein, a strong predictor for acute coronary heart disease events in apparently healthy, middle-aged men from the general population. Circulation. 2005;112:651–657.
4. Fuhrman B, Rosenblat M, Hayek T, Coleman R, Aviram M. Ginger extract consumption reduces plasma cholesterol, inhibits LDL oxidation and attenuates development of atherosclerosis in atherosclerotic, apolipoprotein E-deficient mice. J Nutr. 2000;130:1124–1131.
5. Ruslay S, Abas F, Shaari K, et al. Characterization of the components present in the active fractions of health gingers (Curcuma xanthorrhiza and Zingiber zerumbet) by HPLC–DAD–ESIMS. Food Chem. 2007; 104:1183–1191.
6. Yob N, Jofrry SM, Affandi M, Teh L, Salleh M, Zakaria Z. Zingiber zerumbet (L.) Smith: a review of its ethnomedicinal, chemical, and pharmacological uses. Evid Based Complement Alternat Med. 2011;2011:543216.
7. Chang CJ, Tzeng TF, Liou SS, Chang YS, Liu IM. Regulation of lipid disorders by ethanol extracts from Zingiber zerumbet in high-fat diet-induced rats. Food Chem. 2012;132:460–467.
8. Duve R. Highlights of the chemistry and pharmacology of wild ginger (Zingiber zerumbet Smith). Fiji Agri J. 1980;42:41–43.
9. Kitayama T. Attractive reactivity of a natural product, zerumbone. Biosci Biotechnol Biochem. 2011;75:199–207.
10. Murakami A, Takahashi D, Kinoshita T, et al. Zerumbone, a Southeast Asian ginger sesquiterpene, markedly suppresses free radical generation, proinflammatory protein production, and cancer cell proliferation accompanied by apoptosis: the α, β-unsaturated carbonyl group is a prerequisite. Carcinogenesis. 2002;23:795–802.
11. Schulze PC, Lee RT. Oxidative stress and atherosclerosis. Curr Atheroscler Rep. 2005;7:242–248.
12. Murakami A, Ohigashi H. Cancer-preventive anti-oxidants that attenuate free radical generation by inflammatory cells. Biol Chem. 2006; 387:387–392.
13. Song L, Leung C, Schindler C. Lymphocytes are important in early atherosclerosis. J Clin Invest. 2001;108:251–259.
14. Galkina E, Ley K. Immune and inflammatory mechanisms of atherosclerosis. Annu Rev Immunol. 2009;27:165–197.
15. Eguchi A, Kaneko Y, Murakami A, Ohigashi H. Zerumbone suppresses phorbol ester-induced expression of multiple scavenger receptor genes in THP-1 human monocytic cells. Biosci Biotechnol Biochem. 2007;71:935–945.
16. Ohta H, Wada H, Niwa T, et al. Disruption of tumor necrosis factor-α gene diminishes the development of atherosclerosis in ApoE-deficient mice. Atherosclerosis. 2005;180:11–17.
17. Rahman HS, Rasedee A, How CW, et al. Zerumbone-loaded nanostructured lipid carriers: preparation, characterization, and antileukemic effect. Int J Nanomedicine. 2013;8:2769–2781.
18. Al-Saffar FJ, Ganabadi S, Fakurazi S, Yaakub H. Zerumbone improved immunoreactivity of neuropeptides in monosodium iodoacetate induced knee osteoarthritis in rat. African J Biotech. 2011;10:3646–3653.
19. Shiomi M, Yamada S, Ito T. Atheroma stabilizing effects of simvastatin due to depression of macrophages or lipid accumulation in the atheromatous plaques of coronary plaque-prone WHHL rabbits. Atherosclerosis. 2005;178:287–294.
20. Hernández-Presa MA, Ortego M, Tuñón J, et al. Simvastatin reduces NF-κB activity in peripheral mononuclear and in plaque cells of rabbit atheroma more markedly than lipid lowering diet. Cardiovasc Res. 2003;57:168–177.
21. Charoenwanthanang P, Lawanprasert S, Phivthong-Ngam L, Piyachaturawat P, Sanvarinda Y, Porntadavity S. Effects of Curcuma comosa on the expression of atherosclerosis-related cytokine genes in rabbits fed a high-cholesterol diet. J Ethnopharmacol. 2011;134:608–613.
22. Gómez-Garre D, Muñoz-Pacheco P, González-Rubio M, Aragoncillo P, Granados R, Fernández-Cruz A. Ezetimibe reduces plaque inflammation in a rabbit model of atherosclerosis and inhibits monocyte migration in addition to its lipid-lowering effect. Br J Pharmacol. 2009; 156:1218–1227.
23. Prasad K. Reduction of serum cholesterol and hypercholesterolemic atherosclerosis in rabbits by secoisolariciresinol diglucoside isolated from flaxseed. Circulation. 1999;99:1355–1362.
24. Campbell JH, Efendy JL, Smith NJ, Campbell GR. Molecular basis by which garlic suppresses atherosclerosis. J Nutr. 2001;131: 1006S–1009S.
25. Nurulhuda MH, Azlan A, Ismail A, Amom Z, Shakirin FH. Cholesterol-lowering and atherosclerosis inhibitory effect of Sibu olive in cholesterol fed-rabbit. Asian J Biochem. 2012;7:80–89.
26. Zulkhairi A, Zaiton Z, Jamaluddin M, et al. Alpha lipoic acid posses dual antioxidant and lipid lowering properties in atherosclerotic-induced New Zealand White rabbit. Biomed Pharmacother. 2008;62:716–722.
27. Yanni AE. The laboratory rabbit: an animal model of atherosclerosis research. Lab Anim. 2004;38:246–256.
28. Luna LG, editor. Manual of Histologic Staining Methods of the Armed Forces Institute of Pathology. New York: Blakiston Division, McGraw-Hill; 1968.
29. Moghadasian MH. Experimental atherosclerosis: a historical overview. Life Sci. 2002;70:855–865.
30. Prasad K. Regression of hypercholesterolemic atherosclerosis in rabbits by secoisolariciresinol diglucoside isolated from flaxseed. Atherosclerosis. 2008;197:34–42.
31. Liang J, Liu E, Yu Y, et al. Macrophage metalloelastase accelerates the progression of atherosclerosis in transgenic rabbits. Circulation. 2006; 113:1993–2001.
32. Zheng S, Qian Z, Tang F, Sheng L. Suppression of vascular cell adhesion molecule-1 expression by crocetin contributes to attenuation of atherosclerosis in hypercholesterolemic rabbits. Biochem Pharmacol. 2005;70:1192–1199.
33. Bocan T, Mueller SB, Mazur MJ, Uhlendorf PD, Brown EQ, Kieft KA. The relationship between the degree of dietary-induced hypercholesterolemia in the rabbit and atherosclerotic lesion formation. Atherosclerosis. 1993;102:9–22.
34. Hakimoğlu F, Kizıi G, Kanay Z, Kizil M, Isi H. The effect of ethanol extract of Hypericum lysimachioides on lipid profile in hypercholesterolemic rabbits and its in vitro antioxidant activity. Atherosclerosis. 2007;192:113–122.
35. Lapenna D, Ciofani G, Pierdomenico SD, Giamberardino MA, Cuccurullo F. Reaction conditions affecting the relationship between thiobarbituric acid reactivity and lipid peroxides in human plasma. Free Radic Biol Med. 2001;31:331–335.
36. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem. 1979;95:351–358.
37. Marklund S, Marklund G. Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur J Biochem. 1974;47:469–474.
38. Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem. 1997;272:20963–20966.
39. Chisolm GM, Steinberg D. The oxidative modification hypothesis of atherogenesis: an overview. Free Radic Biol Med. 2000;28:1815–1826.
40. Castelli WP. Lipids, risk factors and ischaemic heart disease. Atherosclerosis. 1996;124 Suppl:S1–S9.
41. Chapman MJ, Ginsberg HN, Amarenco P, et al; European Atherosclerosis Society Consensus Panel. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J. 2011;32:1345–1361.
42. Toth PP, Davidson MH. High-density lipoproteins: marker of cardiovascular risk and therapeutic target. J Clin Lipidol. 2010;4:359–364.
43. Sharma I, Gusain D, Dixit VP. Hypolipidemic and antiatherosclerotic effects of Zingiber officinale in cholesterol fed rabbits. Phytomeicine Res. 1996;10:517–518.
44. Bhandari U, Sharma J, Zafar R. The protective action of ethanolic ginger (Zingiber officinale) extract in cholesterol fed rabbits. J Ethnopharmacol. 1998;61:167–171.
45. Ahmed RS, Suke SG, Seth V, Chakraborti A, Tripathi AK, Banerjee BD. Protective effects of dietary ginger (Zingiber officinales Rosc.) on lindane-induced oxidative stress in rats. Phytother Res. 2008; 22:902–906.
46. Gerrity R. The role of the monocyte in atherogenesis: I. Transition of blood-borne monocytes into foam cells in fatty lesions. Am J Pathol. 1981;103:181–190.
47. Bhandari U, Pillai K. Effect of ethanolic extract of Zingiber officinale on dyslipidaemia in diabetic rats. J Ethnopharmacol. 2005;97:227–230.
48. Verma SK, Singh M, Jain P, Bordia A. Protective effect of ginger, Zingiber officinale Rosc on experimental atherosclerosis in rabbits. Indian J Exp Biol. 2004;42:736–738.
49. Nammi S, Sreemantula S, Roufogalis BD. Protective Effects of Ethanolic Extract of Zingiber officinale Rhizome on the Development of Metabolic Syndrome in High-Fat Diet-Fed Rats. Basic Clin Pharmacol Toxicol. 2009;104:366–373.
50. Nammi S, Kim MS, Gavande NS, Li GQ, Roufogalis BD. Regulation of low-density lipoprotein receptor and 3-hydroxy-3-methylglutaryl coenzyme A reductase expression by Zingiber officinale in the liver of high-fat diet-fed rats. Basic Clin Pharmacol Toxicol. 2010;106:389–395.
51. Srinivasan K, Sambaiah K. The effect of spices on cholesterol 7 alpha-hydroxylase activity and on serum and hepatic cholesterol levels in the rat. Int J Vitam Nutr Res. 1991;61:364–369.
52. Badimon J, Fuster V, Chesebro J, Badimon L. Coronary atherosclerosis. A multifactorial disease. Circulation. 1993;87:113–116.
53. Malloy MJ, Kane JP. Hyperlipidemia and cardiovascular disease. Curr Opin Lipidol. 2012;23:591–592.
54. Gotto AM Jr, Grundy SM. Lowering LDL cholesterol: questions from recent meta-analyses and subset analyses of clinical trial data issues from the Interdisciplinary Council on Reducing the Risk for Coronary Heart Disease, ninth Council meeting. Circulation. 1999;99:E1–E7.
55. Zeng Y, Song JX, Shen XC. Herbal remedies supply a novel prospect for the treatment of atherosclerosis: a review of current mechanism studies. Phytother Res. 2012;26:159–167.
56. Mashour NH, Lin GI, Frishman WH. Herbal medicine for the treatment of cardiovascular disease: clinical considerations. Arch Intern Med. 1998;158:2225–2234.
57. Jasuja ND. Hypocholesterolemic and antioxidant potentials of some plants and herbs: a review. J Zool Sci. 2013;1(2):26–42.
58. Ness GC, Zhao Z, Lopez D. Inhibitors of cholesterol biosynthesis increase hepatic low-density lipoprotein receptor protein degradation. Arch Biochem Biophys. 1996;325:242–248.
59. Libby P, Geng YJ, Aikawa M, et al. Macrophages and atherosclerotic plaque stability. Curr Opin Lipidol. 1996;7:330–335.
60. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135–1143.
61. Hegele RA. The pathogenesis of atherosclerosis. Clinica Chimica Acta. 1996;246(1–2):21–38.
62. Freedman JE. High-fat diets and cardiovascular diseaseAre nutritional supplements useful? J Am Coll Cardiol. 2003;41:1750–1752.
63. Madamanchi NR, Vendrov A, Runge MS. Oxidative stress and vascular disease. Arterioscler Thromb Vasc Biol. 2005;25:29–38.
64. Singh U, Jialal I. Oxidative stress and atherosclerosis. Pathophysiology. 2006;13:129–142.
65. Fearon IM, Faux SP. Oxidative stress and cardiovascular disease: novel tools give (free) radical insight. J Mol Cell Cardiol. 2009;47: 372–381.
66. Heistad DD, Wakisaka Y, Miller J, Chu Y, Pena-Silva R. Novel aspects of oxidative stress in cardiovascular diseases. Circ J. 2009;73: 201–207.
67. Schwenke DC, Behr SR. Vitamin E combined with selenium inhibits atherosclerosis in hypercholesterolemic rabbits independently of effects on plasma cholesterol concentrations. Circ Res. 1998;83:366–377.
68. Kaliora A, Dedoussis G, Schmidt H. Dietary antioxidants in preventing atherogenesis. Atherosclerosis. 2006;187:1–17.
69. Shukla SK, Gupta S, Ojha SK, Sharma SB. Cardiovascular friendly natural products: a promising approach in the management of CVD. Nat Prod Res. 2010;24:873–898.
70. Al-Saffar F, Ganabadi S, Fakurazi S, Yaakub H. Response of hepatic metabolizing enzymes and oxidative stress in orally administrated zerumbone against MIA-induced osteoarthritis in rats. J Animal Vet Adv.2011;10:566–573.
71. Murakami A, Takahashi D, Koshimizu K, Ohigashi H. Synergistic suppression of superoxide and nitric oxide generation from inflammatory cells by combined food factors. Mutat Res. 2003;523:151–161.